CD8A and neoplasm: The outcomes of the combined therapy demonstrated notable enhancements in antitumor effectiveness, driven by an increase in both the number and activity of CD8+ T cells, alongside a decrease in Treg numbers within tumors and the associated lymph nodes in TNBC, colon, and lung syngeneic tumor models [25].